Figure 4. Attenuation of TGF-β-induced myofibroblast differentiation by the ANO1 inhibitor, T16Ainh-A01.
A, Representative images of western blot analyses of the effect of the pharmacological inhibitor of ANO1, T16Ainh-A01 (T16Ai) on myofibroblast differentiation. Serum-starved (48 hr) HLF were pretreated with 30 μM T16Ai or vehicle control for 1hr, followed by treatment with TGF-β (1 ng/ml) for 48 hr. Cell lysates were then probed for immunoreactivity of anactomin-1 (ANO1), collagen 1A1 (Col1A1), fibronectin (FN), and smooth muscle α-actin (SMA). B, Quantification of ANO1, Col1A1, FN, and SMA immunoreactivities. Data are mean values ± SD. *p<0.05, **p<0.01, ***p<0.001, vs. TGFβ group, Kruskal-Wallis test with Dunn’s post hoc correction. Brace brackets, ###p<0.001; ####, p<0.0001, are the results of preplanned comparisons of TGF-β effect with and without ANO1 inhibitor, one-population t-test.